In the complex and data-intensive realm of drug discovery, the importance of thoughtful data generation cannot be overstated. Strategic data collection is fundamental to transforming early-stage discovery and compound optimization processes. High-quality, purpose-driven data enhances AI/ML modeling, accelerates the identification of promising compounds, focuses costly experimentation, and streamlines discovery pipelines.
As an example, I will refer to AI/ML-driven active learning approaches integrated into experimental discovery pipelines, which enable early safety warnings. This active learning not only enhances safety assessments but also refines AI/ML models, making the entire discovery process more efficient and reliable.
The integration of multimodal data at scale—encompassing diverse compound descriptors such as chemical structures, experimental assay readouts, and omics data—facilitates a more holistic representation of molecules, where similarities are not solely based on chemical structure.
This comprehensive data fusion improves the learning of molecular properties, including potency and ADMET, leading to better model performance and more robust generalization over extended discovery timelines. Building on this foundation, such models can also be employed to infer in-vivo pharmacokinetic (PK) parameters, which can be used for human dose projection.
This approach enables the prioritization of compounds for in-vivo testing, thereby reducing unnecessary animal experiments and promoting more ethical and efficient drug discovery.
Last but not least, achieving breakthroughs in drug discovery also demands a significant shift in mindset and organizational practices. Embracing technological innovation, fostering agility, and cultivating a culture of continuous learning are essential to unlocking new possibilities.
%20from%20Novo%20Nordisk.webp)
%20(18).webp)
